Immunic, Inc. (IMUX)

Oncternal Therapeutics Statistics

Total Valuation

Immunic has a market cap or net worth of $86.03 million. The enterprise value is $30.93 million.

Market Cap	86.03M
Enterprise Value	30.93M

Important Dates

The last earnings date was Thursday, August 7, 2025, before market open.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Immunic has 98.65 million shares outstanding. The number of shares has increased by 50.88% in one year.

Current Share Class	98.65M
Shares Outstanding	98.65M
Shares Change (YoY)	+50.88%
Shares Change (QoQ)	+30.42%
Owned by Insiders (%)	1.76%
Owned by Institutions (%)	32.41%
Float	76.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.40
P/TBV Ratio	2.54
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.19, with a Debt / Equity ratio of 0.01.

Current Ratio	2.19
Quick Ratio	2.03
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -208.93% and return on invested capital (ROIC) is -133.39%.

Return on Equity (ROE)	-208.93%
Return on Assets (ROA)	-88.95%
Return on Invested Capital (ROIC)	-133.39%
Return on Capital Employed (ROCE)	-308.55%
Revenue Per Employee	n/a
Profits Per Employee	-$1.12M
Employee Count	91
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.46% in the last 52 weeks. The beta is 1.39, so Immunic's price volatility has been higher than the market average.

Beta (5Y)	1.39
52-Week Price Change	-25.46%
50-Day Moving Average	0.84
200-Day Moving Average	1.03
Relative Strength Index (RSI)	44.49
Average Volume (20 Days)	1,121,723

Short Selling Information

The latest short interest is 8.56 million, so 8.68% of the outstanding shares have been sold short.

Short Interest	8.56M
Short Previous Month	8.95M
Short % of Shares Out	8.68%
Short % of Float	11.23%
Short Ratio (days to cover)	5.34

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-105.27M
Pretax Income	-95.31M
Net Income	-101.84M
EBITDA	-105.10M
EBIT	-105.27M
Earnings Per Share (EPS)	-$0.94

Balance Sheet

The company has $55.31 million in cash and $205,000 in debt, giving a net cash position of $55.11 million or $0.56 per share.

Cash & Cash Equivalents	55.31M
Total Debt	205,000
Net Cash	55.11M
Net Cash Per Share	$0.56
Equity (Book Value)	33.91M
Book Value Per Share	0.26
Working Capital	32.53M

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immunic does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-50.88%
Shareholder Yield	-50.88%
Earnings Yield	-118.37%
FCF Yield	n/a

Analyst Forecast

The average price target for Immunic is $7.50, which is 759.99% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$7.50
Price Target Difference	759.99%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a